Navigation Links
Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse
Date:7/23/2014

LONDON, July 23, 2014 /PRNewswire/ -- Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has filed an investigational new drug application ("IND") with respect to its naloxone-based opioid overdose reversal nasal spray. Lightlake also announced today that it has received an additional commitment from the National Institute on Drug Abuse ("NIDA"), part of the National Institutes of Health ("NIH"), to fund a second study with respect to Lightlake's nasal spray. Lightlake, in collaboration with NIDA, previously commenced a clinical trial with respect to its nasal spray in September 2013.

Naloxone is an injectable medicine that can rapidly reverse the overdose of prescription and illicit opioids. Lightlake has been developing a naloxone nasal spray that could widely expand its availability and use in preventing opioid overdose deaths, a public health problem of epidemic proportion in the United States. In collaboration with NIDA, Lightlake will now evaluate its technology on a larger population, which will be a key step towards approval in the United States and other worldwide regions.

"We are extremely pleased that NIDA has continued its support of our opioid overdose reversal treatment," said Dr. Roger Crystal, CEO of Lightlake. "This support demonstrates NIDA's commitment of having an FDA approved intranasal naloxone nasal spray available to the public."

"NIDA's continued commitment to advancing our overdose reversal treatment reflects their confidence in the potential of our treatment," said Kevin Pollack, CFO of Lightlake. "We believe that our treatment can make a huge difference in addressing the overdose epidemic and save a significant number of lives, and NIDA's support plays a critical role in achieving our goals."

About Lightlake Therapeutics Inc.

Lightlake Therapeutics Inc., a biopharmaceutical company, is using its expertise in opioid antagonists to build a platform of innovative intranasal naloxone solutions to common addictions and related disorders. Lightlake is developing a treatment to reverse opioid overdoses, which have reached epidemic proportions in the United States. Lightlake has successfully completed a clinical trial for this treatment in collaboration with the National Institute on Drug Abuse, part of the National Institutes of Health. Lightlake also has successfully completed a Phase II clinical trial to treat Binge Eating Disorder. For more information please visit: http://www.lightlaketherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

Corporate Contact:
Lightlake Therapeutics Inc.
Dr. Roger Crystal, CEO
+44(0)203 617 8739
info@lightlaketherapeutics.com

Investor Relations Contact:
Booke and Company, Inc.
212-490-9095
admin@bookeandco.com


'/>"/>
SOURCE Lightlake Therapeutics Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Initial Data from Lightlake Therapeutics Joint Clinical Trial with NIDA Shows Nasal Delivery of Naloxone for Opioid Overdose as a Promising Treatment
2. Lightlake Therapeutics to Present at 6th Annual LD MICRO Conference
3. Lightlake Therapeutics Retains KCSA Strategic Communications as Corporate Communications Advisors
4. Particle Sciences and Eyeon Therapeutics Receive Patent on Novel Dry Eye Technology
5. MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics
6. Echo Therapeutics to Present at the Noble Financial Capital Markets Tenth Annual Equity Conference
7. Spark Therapeutics Achieves Recruitment Goal in Phase 3 Gene Therapy Clinical Study for Inherited Blindness
8. Echo Therapeutics Hires Product Development Management Executive
9. Cell Therapeutics Announces 2014 Outlook and Recent Drug Portfolio Progress
10. Halozyme Therapeutics Provides an Update on Anticipated Milestones for 2014 at the 32nd Annual J. P. Morgan Healthcare Conference
11. Lilly Announces Acquisition of CGRP Antibody for Migraine Prevention from Arteaus Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... 16, 2017  Newly published research from the CVS ... the role a private retailer can play in restricting ... published online today in the American Journal of ... remove tobacco from all CVS Pharmacy stores reduced the ... an even greater impact on those who bought cigarettes ...
(Date:2/16/2017)... -- Summary Provides understanding and access to the ... healthcare companies. ... The Global Allergy Partnering Terms and Agreements since 2010 report ... by the world,s leading healthcare companies. - Trends ... Deals listed by company A-Z, industry sector, stage of development, technology ...
(Date:2/16/2017)... , Feb 16, 2017 Research and Markets ... Diagnostics Market Analysis & Trends - Function, Application, Cancer Type, Technology ... ... Cancer Diagnostics Market is poised to grow at a CAGR of ... by 2025. Some of the prominent trends ...
Breaking Medicine Technology:
(Date:2/19/2017)... ... , ... ProBrand Glitch is a set of 30 glitch distortion logo reveals made exclusively for ... logo with a glitch reveal in just a few clicks of a mouse. Customizable glitch ... each preset. Use these presets to add a uniquely animated logo to any photos or ...
(Date:2/18/2017)... VA (PRWEB) , ... February ... ... of Change for Devicemakers , Sponsored by Axendia, **FDAnews Free Webinar**, March ... , Are manufacturers looking to reduce their regulatory burden? Pay dividends in ...
(Date:2/18/2017)... , ... February 17, 2017 , ... ... drvallecillos.com , Beverly Hills plastic surgeon Dr. Glenn Vallecillos ... , Dr. Vallecillos says, "Traditionally, plastic surgery has been centered around that idea ...
(Date:2/18/2017)... La. (PRWEB) , ... February 18, 2017 , ... ... released today provides the latest information and contact points to easily connect elderly ... home care, assisted living, and elder-care funding. It also conveys material on this ...
(Date:2/17/2017)... Diego, CA (PRWEB) , ... February 17, 2017 ... ... initiative—InvestUp—to focus on foundational and sustainable systems change designed to further positively impact ... , “The Board of Trustees has long considered it our duty to seriously ...
Breaking Medicine News(10 mins):